Gary Owens, Mesa Laboratories CEO
September 14, 2021 10:32 AM EDT
Deals

Ser­vices firm Mesa buys out mol­e­c­u­lar di­ag­nos­tics play­er for a cool $300M as ge­net­ics test­ing gains steam

Josh Sullivan

The rise in ge­net­ic test­ing has spurred a rev­o­lu­tion in drug de­vel­op­ment, and now a bio­phar­ma ser­vices firm is look­ing to jump on board in …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Ap­plied Ther­a­peu­tic­s' rare dis­ease drug gets a CRL

No­var­tis to cut 139 jobs in NJ as part of com­mer­cial re­fo­cus

PTC re­ports Phase 2 ALS fail, sells pri­or­i­ty re­view vouch­er for $150M

Nor­bert Bischof­berg­er's time as Kro­nos CEO ends as biotech seeks new life

FDA is look­ing in­to hema­tol­ogy risks af­ter pa­tients take Blue­bird's Skysona gene ther­a­py

To lead NIH, Trump taps Stan­ford aca­d­e­m­ic and pan­dem­ic re­sponse crit­ic Jay Bhat­tacharya

A service from the Financial Times